CNS Digital Biomarkers Update

BioDigit Home Includes more than 100 Digital Assessments 

BioDigit Home - the most comprehensive solution for the measurement of digital biomarkers in CNS diseases - now includes more than 100 digital assessments. These assessments span motor, cognition, and speech functions, as well as mental health. 

When used in conjunction with BoSensics’ wearable sensors, they provide a powerful and highly customizable patient monitoring solution for CNS studies and clinical trials, covering physical activity, posture, falls and fall risk, gait and balance, as well as cognition, motor symptoms, speech and voice biomarkers. 

Digital Biomarker Study in Huntington's Disease

We recently completed one of the largest digital biomarker studies in Huntington's Disease ever conducted. The study was supported by a $2.5M NIH funding award to BioSensics, conducted in collaboration with the University of Rochester.

44 participants with clinically diagnosed HD or prodromal HD were followed for up to 2.5 years. Study results have been presented at multiple conferences and additional manuscripts are in preparation. Highlights include:

1. Development of a first-in-kind wearable sensor for continuous monitoring of chorea.

2. Physical activity parameters, as measured by the PAMSys sensor, provide more sensitive and objective measures of disease progression compared to clinical ratings (e.g., UHDRS).

3. Fall and near-fall are important symptoms of HD, with HD patients who are not on anti-chorea medication shown to be more prone to falls.

4. Development of speech analysis models for an automatic rating of dysarthria in HD. 

The data collected in this study are included in the BioDigit Database - The largest database of digital biomarkers in CNS. 

We look forward to attending this year's MDA Clinical & Scientific Conference in Nashville, TN on March 13-16th where we will present a poster related to our study in ataxia. If you are attending please stop by our booth #218.

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that develops and provides end-to-end solutions and services for the collection of digital measures and biomarkers in clinical trials and research. All components of BioSensics solutions, including the wearable sensors, software, and algorithms are developed and validated by BioSensics. Our experienced research team provides comprehensive technical and scientific consulting, including study design and protocol development support, as well as statistical analysis. In addition, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

The U.S. National Institute of Health (NIH) has awarded BioSensics over $50M to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.